Mallinckrodt Ard, Inc.
Volume 164 · 164 F.T.C. 1060
Cite this decision
Mallinckrodt Ard, Inc., 164 F.T.C. 1060 (2017). Consumer Law Library, https://consumerlawlibrary.org/decisions/v164-0019
Report an error in this record (decision id v164-0019)
Cited by 0 later FTC decisions
Cites
Text (OCR of the scan at left; may contain errors)
IN THE MATTER OF MALLINCKRODT ARD, INC.
AND MALLINCKRODT PLC Docket No. X170029. Order, July 12, 2017 Letter approving Mallinckrodt’s Synacthen Sublicense with West Therapeutic Development, LLC.
LETTER APPROVING SUBLICENSE AGREEMENT Kenneth S. Reinker, Esq.
Cleary Gottlieb Steen & Hamilton LLP Re: Stipulated Order for Permanent Injunction and Equitable Monetary Relief, FTC v. Mallinckrodt ARD, Inc. and Mallinckrodt plc, No. 1:17-cv-120 (D.D.C. Jan. 30, 2017); FTC File No. 131 0172; FTC Matter No. X170029 Dear Mr. Reinker:
This is in reference to the Application for Approval of Proposed Synacthen Sublicense (“Application”) filed by Mallinckrodt ARD, Inc. and Mallinckrodt plc (collectively, “Mallinckrodt”) and received on June 30, 2017. Pursuant to the Stipulated Order for Permanent Injunction and Equitable Monetary Relief (“Order”) in this matter, Mallinckrodt requests that the Commission approve its proposed Synacthen Sublicense by and between Mallinckrodt and West Therapeutic Development, LLC (“West”).
After consideration of Mallinckrodt’s Application and other available information, the Commission has approved the proposed Synacthen Sublicense to West as required by the Synacthen Sublicense and Order. In according its approval, the Commission has relied upon the information submitted and the representations made by Mallinckrodt in connection with Mallinckrodt’s Application and has assumed them to be accurate and complete. By direction of the Commission.
HOLCIM LTD. 1061 Interlocutory Orders, Etc.